NICE Implementation Collaborative (NIC)
The NIC is a unique partnership between the NHS, Life Sciences industry, Healthcare professional bodies, key health organisations and Patient groups. NIC partners are committed to working together to support a system where patients have faster and more consistent access to NICE-recommended medicines, treatments and technologies and is a collaboration which completely re-draws the landscape. Industry will now work with academia, clinical groups, NHS England, NICE and representative bodies to drive compliance with NICE recommendations.
The partnership underpinned by the signing of a concordat in March 2013. The Concordat is made up of the following members:
- Academy of Medical Royal Colleges
- Association of British Healthcare Industries (ABHI)
- Foundation Trust Network
- NHS Alliance NHS
- Commissioning Assembly
- NHS Confederation
- NHS England
- National Institute for Health and Care Excellence (NICE)
- Patients Involved in NICE
- Royal Pharmaceutical Society
- The Academy of Medical Sciences
- The Association of the British Pharmaceutical Industry (ABPI)
- The British In Vitro Diagnostics Association (BIVDA)
What does the NIC do?
- Identify practical measures that support and promote timely and consistent implementation of NICE Technology Appraisals throughout the NHS in England
- Work jointly to support and promote the adoption of all other forms of NICE guidance that apply to the NHS in England, and to drive the uptake of innovation, in a way that is consistent with local health needs and priorities
- Understand the barriers that restrict expected levels of implementation and uptake, including the requirement for CCGs to provide care for their populations taking into account local affordability and clinical need. The NIC will identify practical measures that its members and all organisations providing NHS services to patients can take to help overcome these barriers
- Support a culture shift within the NHS in favour of clinically- and cost-effective innovation
|Latest NIC work streams|
|Recent NIC work streams|
Denosumab (NICE TA204)
|Denosumab (Prolia) is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and is administered in the form of a 6-monthly subcutaneous injection. It is a £1/day treatment for osteoporosis, recommended in NICE Technology Appraisial 204.|
Denosumab is a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures who are unsuitable (contraindicated,intolerant or unable to comply with special instructions for administration) to oral bisphosphonates (alendronate and either risedronate or etidronate) and have a combination of T-score, age and number of independent clinical risk factors for fracture, and for secondary prevention of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures who are unsuitable to oral bisphosphonates. NICE TA 204 was published on October 2010. However in early 2013 only 11% of PCTs had any guidance or formulary inclusion for denosumab and 28% continue to have denosumab restricted to secondary care use only. In 47% of PCTs there continues to be no funding agreed for denosumab, and in 55% of hospitals have no or limited funding in place.
This inconsistency of availability to patients, balanced by the benefits of treatment is why Denosumab was selected as one of the NIC pilots.
What are the barriers to uptake of NICE guidance?
The NIC has worked with the system to better understand the barriers that exist to the adoption of Denosumab in the treatment of osteoporosis. These include:
|Relevant NIC documents|